Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jan 1;22(1):301-304.
doi: 10.31557/APJCP.2021.22.1.301.

Randomized Study of enterade® to Reduce Diarrhea in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation

Zachariah De Filipp  1 , Brett Glotzbecker  2 , Laura Luque  3 , Haesook T Kim  4 , Katherine M Mitchell  3 , Samuel N Cheuvront  3 , Robert J Soiffer  2
Affiliations
Randomized Controlled Trial

Randomized Study of enterade® to Reduce Diarrhea in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation

Zachariah De Filipp et al. Asian Pac J Cancer Prev. .

Abstract

High-dose chemotherapy frequently causes injury to the gastrointestinal mucosa, resulting in diarrhea. The purpose of the current study was to assess the tolerability and efficacy of enterade® in reducing ≥ grade 2 diarrhea (G2D) in association with high-dose melphalan followed by autologous stem cell transplantation (ASCT). We conducted a prospective, double blinded, multi-center trial in which 114 subjects were randomized to receive enterade® or placebo twice daily during the transplant hospitalization. Gastrointestinal toxicities (nausea, vomiting, oral mucositis and dysphagia) resulted in poor study compliance in both arms. Among subjects who were able to complete planned therapy (13%), the incidence of G2D was lower for those receiving enterade® as compared to placebo (16% vs 86%, p <0.03). Twice daily oral administration of enterade® and placebo following high-dose chemotherapy and ASCT was not feasible due to significant gastrointestinal toxicities. Future explorations of enterade® should be conducted in populations capable of reasonable oral intake.<br />.

Keywords: Amino acids; Chemotherapy; diarrhea: melphalan; medical-food.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study Design
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gupta R, Yin L, Grosche A, et al. An amino acid-based oral rehydration solution regulated radiation-induced intestinal barrier disruption in mice. J Nutr. 2020;150:1100–8. - PubMed
    1. Hendrie JD, Chauhan A, Nelson NR, Anthony LB. Can an amino acid-based oral rehydration solution be effective in managing immune therapy-induced diarrhea? Med Hypotheses. 2019;127:66–70. - PMC - PubMed
    1. Kewalramani T, Nimer SD, Zelenetz AD, et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory hodgkin’s disease or aggressive non-hodgkin’s lymphoma. Bone Marrow Transplant. 2003;32:673–9. - PubMed
    1. Kiss N, Seymour JF, Prince HM, Dutu G. Challenges and outcomes of a randomized study of early nutrition support during autologous stem-cell transplantation. Curr Oncol. 2014;21:E334–9. - PMC - PubMed
    1. Krishna Sg, Zhao W, Grazziutti M, et al. incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications. Cancer. 2011;117:648–55. - PubMed

Publication types

MeSH terms